359 Developing human placental CD34-derived natural killer cells with high affinity and cleavage resistant CD16 and secreted IL-15 (CYNK-201) for cancer immunotherapy

• Lin Kang,
• Robert Hariri,
• Shuyang He,
• Irene Raitman,
• Valentina Rousseva,
• Adrian Kilcoyne,
• Marina Gergues,
• Yuechao Zhao,
• Shengchen Lin,
• Siyara Kilcoyne

Affiliations

Lin Kang

Aff1 Celgene Cellular Therapeutics Warren NJ USA

Robert Hariri

Celularity Inc, Florham Park, New Jersey, USA

Shuyang He

Celularity Inc, Florham Park, New Jersey, USA

Irene Raitman

Celularity, Florham Park, NJ, USA

Valentina Rousseva

Celularity, Florham Park, NJ, USA

Adrian Kilcoyne

Humanigen Inc, Burlingame, California, USA

Marina Gergues

Celularity Inc., Florham Park, NJ, USA

Yuechao Zhao

Celularity Inc., Florham Park, NJ, USA

Shengchen Lin

Celularity Inc., Florham Park, NJ, USA

Siyara Kilcoyne

Celularity Inc., Florham Park, NJ, USA